Kazia Therapeutics (KZIA) vs Xilio Therapeutics (XLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xilio Therapeutics (XLO) has outperformed Kazia Therapeutics (KZIA) over the past year, losing 28.3% versus a loss of 41.1%. Over five years, XLO leads with a -97.3% price change compared with -99.0% for KZIA. Kazia Therapeutics is the larger company by market cap ($56.2 million vs $53.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KZIA | XLO |
|---|---|---|
| Share price | $4.92 | $7.56 |
| Market cap | $56.22M | $53.40M |
| 1-day change | -8.38% | -1.11% |
| YTD return | -28.59% | -15.63% |
| 1-year return | -41.08% | -28.29% |
| 5-year return | -99.01% | -97.29% |
| P/E ratio (TTM) | — | 11.63 |
| EPS (TTM) | $-6.85 | $0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $43.77M |
| Revenue growth (YoY) | — | +589.88% |
| Net income (latest FY) | — | $-35.04M |
| Operating margin | — | -95.92% |
| Net margin | — | -80.05% |
| 52-week high | $17.40 | $10.71 |
| 52-week low | $4.50 | $6.47 |
| Distance from 52-week high | -71.72% | -29.41% |
| Analyst consensus | none | none |
| Avg. price target upside | +476.02% | +164.55% |
| Average volume | 307.30K | 11.54K |
| Shares outstanding | 11.43M | 7.06M |
| Employees | 6 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XLO has outperformed KZIA by 12.8 percentage points over the past year.
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Xilio Therapeutics
XLO stock →Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
KZIA vs XLO FAQ
Which is bigger, Kazia Therapeutics or Xilio Therapeutics?
Kazia Therapeutics (KZIA) is larger, with a market capitalization of $56.22M compared with $53.40M for Xilio Therapeutics (XLO).
Which stock has performed better over the past year, KZIA or XLO?
XLO returned -28.29% over the past 12 months, compared with -41.08% for KZIA (price return, excluding dividends). Past performance does not predict future results.
Are Kazia Therapeutics and Xilio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.